Association of early life stress and cognitive performance in patients with schizophrenia and healthy controls.

Autor:	Senner F; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Schneider-Axmann T; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany., Kaurani L; German Center of Neurodegenerative Diseases (DZNE), Göttingen 37075, Germany., Zimmermann J; Psychiatrieverbund Oldenburger Land gGmbH, Karl-Jaspers-Klinik, Bad Zwischenahn 26160, Germany., Wiltfang J; German Center of Neurodegenerative Diseases (DZNE), Göttingen 37075, Germany.; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen 37075, Germany.; Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal., von Hagen M; Clinic for Psychiatry and Psychotherapy, Clinical Center Werra-Meißner, Eschwege 37269, Germany., Vogl T; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Spitzer C; Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Rostock, Rostock 18147, Germany., Senner S; Center for Psychiatry Reichenau, Academic Hospital University of Konstanz, Konstanz 78479, Germany., Schulte EC; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Schmauß M; Department of Psychiatry and Psychotherapy, Bezirkskrankenhaus Augsburg, Augsburg 86156, Germany., Schaupp SK; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Reimer J; Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany., Reich-Erkelenz D; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Papiol S; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Kohshour MO; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany.; Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Lang FU; Department of Psychiatry II, Ulm University, Bezirkskrankenhaus Günzburg, Günzburg, 89312, Germany., Konrad C; Department of Psychiatry and Psychotherapy, Agaplesion Diakonieklinikum, Rotenburg 27356, Germany., Kirchner SK; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.; Department of Psychiatry and Psychotherapy, Bezirkskrankenhaus Augsburg, Augsburg 86156, Germany., Kalman JL; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Juckel G; Department of Psychiatry, Ruhr University Bochum, LWL University Hospital, Bochum 44791, Germany., Heilbronner M; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Heilbronner U; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Figge C; Karl-Jaspers Clinic, European Medical School Oldenburg-Groningen, Oldenburg 26160, Germany., Eyl RE; Stuttgart Cancer Center -Tumorzentrum Eva Mayr-Stihl, Klinikum Stuttgart, Stuttgart 70174, Germany., Dietrich D; AMEOS Clinical Center Hildesheim, Hildesheim 31135, Germany., Budde M; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Angelescu IG; Department of Psychiatry and Psychotherapy, Mental Health Institute Berlin, Berlin 14050, Germany., Adorjan K; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany., Schmitt A; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany.; Laboratory of Neuroscience (LIM27), Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil., Fischer A; German Center of Neurodegenerative Diseases (DZNE), Göttingen 37075, Germany.; Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen 37075, Germany.; Cluster of Excellence 'Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells' (MBExC), University of Göttingen, Göttingen, Germany., Falkai P; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich 80336, Germany., Schulze TG; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich 80336, Germany.; Department of Psychiatry and Behavorial Sciences, SUNY Upstate Medical University, Syracuse, 54, NY, USA.; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jazyk:	angličtina
Zdroj:	Schizophrenia research. Cognition [Schizophr Res Cogn] 2023 Feb 11; Vol. 32, pp. 100280. Date of Electronic Publication: 2023 Feb 11 (Print Publication: 2023).
DOI:	10.1016/j.scog.2023.100280
Abstrakt:	As core symptoms of schizophrenia, cognitive deficits contribute substantially to poor outcomes. Early life stress (ELS) can negatively affect cognition in patients with schizophrenia and healthy controls, but the exact nature of the mediating factors is unclear. Therefore, we investigated how ELS, education, and symptom burden are related to cognitive performance. The sample comprised 215 patients with schizophrenia (age, 42.9 ± 12.0 years; 66.0 % male) and 197 healthy controls (age, 38.5 ± 16.4 years; 39.3 % male) from the PsyCourse Study. ELS was assessed with the Childhood Trauma Screener (CTS). We used analyses of covariance and correlation analyses to investigate the association of total ELS load and ELS subtypes with cognitive performance. ELS was reported by 52.1 % of patients and 24.9 % of controls. Independent of ELS, cognitive performance on neuropsychological tests was lower in patients than controls ( p  < 0.001). ELS load was more closely associated with neurocognitive deficits (cognitive composite score) in controls ( r  = -0.305, p  < 0.001) than in patients ( r  = -0.163, p  = 0.033). Moreover, the higher the ELS load, the more cognitive deficits were found in controls ( r  = -0.200, p  = 0.006), while in patients, this correlation was not significant after adjusting for PANSS. ELS load was more strongly associated with cognitive deficits in healthy controls than in patients. In patients, disease-related positive and negative symptoms may mask the effects of ELS-related cognitive deficits. ELS subtypes were associated with impairments in various cognitive domains. Cognitive deficits appear to be mediated through higher symptom burden and lower educational level. Competing Interests: Ion-George Anghelescu has been member of advisory boards and received speakers honoraria of Janssen-Cilag and Dr. Willmar Schwabe and received speakers honoraria of Recordati. P. Falkai has been an honorary speaker for AstraZeneca, Bristol Myers Squibb, Lilly, Essex, GE Healthcare, GlaxoSmithKline, Janssen Cilag, Lundbeck, Otsuka, Pfizer, Servier, and Takeda and has been a member of the advisory boards of Janssen-Cilag, AstraZeneca, Lilly, Lundbeck, Richter, Recordati and Boehringer Ingelheim. C. Konrad received fees for an educational program from Aristo Pharma, Janssen-Cilag, Lilly, MagVenture, Servier, and Trommsdorff as well as travel support and speakers honoraria from Aristo Pharma, Janssen-Cilag, Lundbeck, Neuraxpharm and Servier. A. Schmitt was an honorary speaker for TAD Pharma and Roche and a member of Roche advisory boards. J. Wiltfang has been an honorary speaker for Actelion, Amgen, Beeijing Yibai Science and Technology Ltd., Janssen Cilag, Med Update GmbH, Pfizer, Roche Pharma, and has been a member of the advisory boards of Abbott, Biogen, Boehringer Ingelheim, Lilly, MSD Sharp & Dohme, and Roche Pharma and receives fees as a consultant for Immungenetics and Roboscreen. All other authors report no conflicts of interest. (© 2023 The Authors. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu